DRD2 and neoplasm: As expected, we observed a decrease in ex vivo tumour weight and volume in cabergoline-treated mice compared with those treated without cabergoline (Fig. 3d–l), suggesting that D2R agonism sensitizes chemotherapy-refractory human SCLC to cisplatin and etoposide.